Home > Compound List > Product Information
Doxacurium chloride_Molecular_structure_CAS_106819-53-8)
Click picture or here to close

Doxacurium chloride

Catalog No. DB01135 Name DrugBank
CAS Number 106819-53-8 Website http://www.ualberta.ca/
M. F. C56H78N2O16++ Telephone (780) 492-3111
M. W. 1035.22232 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 1006

SYNONYMS

IUPAC name
6,7,8-trimethoxy-2-methyl-2-(3-{[4-oxo-4-(3-{6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl}propoxy)butanoyl]oxy}propyl)-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium
IUPAC Traditional name
doxacurii chloridum
Brand Name
Nuromax

DATABASE IDS

PubChem SID 46506733
PubChem CID 60169
CAS Number 106819-53-8

PROPERTIES

DETAILS

Description (English)
Item Information
Drug Groups approved
Description Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration.
Indication Used to provide skeletal muscle relaxation as an adjunct to general anesthesia, for endotracheal intubation or to facilitate mechanical ventilation.
Pharmacology Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant. The neuromuscular block produced by doxacurium chloride may be antagonized by anticholinesterase agents. As with other nondepolarizing neuromuscular blocking agents, the more profound the neuromuscular block at reversal, the longer the time and the greater the dose of anticholinesterase required for recovery of neuromuscular function. Doxacurium chloride is approximately 2.5 to 3 times more potent than pancuronium and 10 to 12 times more potent than metocurine.
Toxicity Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia.
Affected Organisms
Humans and other mammals
Biotransformation In vivo data from humans suggest that doxacurium chloride is not metabolized and that the major elimination pathway is excretion of unchanged drug in urine and bile.
Half Life 99 minutes in normal healthy adults.
Protein Binding Approximately 30%.
Elimination In vivo data from humans suggest that NUROMAX is not metabolized and that the major elimination pathway is excretion of unchanged drug in urine and bile.
Distribution * 0.11-0.43 L/kg [Healthy Young Adult Patients]
* 0.17-0.55 L/kg [Kidney Transplant Patients]
* 0.17-0.35 L/kg [Liver Transplant Patients]
Clearance * 2.66 mL/min/kg [Healthy Young Adult Patients]
* 1.23 mL/min/kg [Kidney Transplant Patients]
* 2.3 mL/min/kg [Liver Transplant Patients]
* 1.75 +/- 0.16 mL/min/kg [Elderly patients (70-83 yrs)]
* 2.54 +/- 0.24 mL/min/kg [younger patients (19-39 yrs)]
References
Martinez EA, Wooldridge AA, Hartsfield SM, Mealey KL: Neuromuscular effects of doxacurium chloride in isoflurane-anesthetized dogs. Vet Surg. 1998 May-Jun;27(3):279-83. [Pubmed]
External Links
Wikipedia
RxList

REFERENCES

  • Martinez EA, Wooldridge AA, Hartsfield SM, Mealey KL: Neuromuscular effects of doxacurium chloride in isoflurane-anesthetized dogs. Vet Surg. 1998 May-Jun;27(3):279-83. Pubmed